Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20417932 | 0.96 | FUCA1 (0.55) | FUCA1S1PR1S1PR5SIGMAR1ACHE | |
| SCHEMBL30875889 | 0.96 | FUCA1 (0.55) | FUCA1S1PR1S1PR5SIGMAR1ACHE | |
| SCHEMBL17560348 | 0.96 | FUCA1 (0.55) | FUCA1S1PR1S1PR5SIGMAR1ACHE | |
| SCHEMBL1514852 | 0.96 | FUCA1 (0.55) | FUCA1S1PR1S1PR5SIGMAR1ACHE | |
| SCHEMBL19518531 | 0.96 | FUCA1 (0.55) | FUCA1S1PR1S1PR5SIGMAR1ACHE | |
| SCHEMBL21220647 | 0.89 | FUCA1 (0.51) | FUCA1S1PR1S1PR5SIGMAR1ACHE | |
| SCHEMBL14529645 | 0.89 | ALDH1A1 (0.53) | FUCA1S1PR1S1PR5SIGMAR1ACHE | |
| SCHEMBL21238086 | 0.89 | FUCA1 (0.51) | FUCA1S1PR1S1PR5SIGMAR1ACHE | |
| SCHEMBL2852290 | 0.89 | FUCA1 (0.51) | FUCA1S1PR1S1PR5SIGMAR1ACHE | |
| SCHEMBL2962712 | 0.89 | FUCA1 (0.58) | FUCA1S1PR1S1PR5SIGMAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173802-B2 | Method for producing piperidin-4-one derivative | NIPPON SODA CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-2058303-B1 | METHOD FOR PRODUCING A PIPERIDIN-4-ONE-DERIVATIVE | NIPPON SODA CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20100004455-A1 | Method for producing piperidin-4-one derivative | NIPPON SODA CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2058303-A1 | METHOD FOR PRODUCING PIPERIDIN-4-ONE-DERIVATIVE | Nippon Soda Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004455-A1 | Method for producing piperidin-4-one derivative | GLUL, ALDH7A1, DDC | FUCA1 1587/4885S1PR1 3336/4885S1PR5 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.